NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against CareDx, Inc. (CDNA) on behalf of CareDx investors. Our investigation concerns whether CareDx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On July 16, 2019, Kerrisdale Capital Research released a report alleging, among other things, that the Company’s diagnostic test, AlloSure, is “fundamentally incapable of identifying the most common type of kidney rejection.” Moreover, the report stated that AlloSure revenues are derived from “protocol usage in clinical testing, which is suffering 20-30% quarterly attrition.”
On this news, shares of CareDX fell as much as 14%, from $37.40 per share to $32.57 per share, thereby injuring investors.
If you purchased or otherwise acquired CareDx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into CareDx, please go to https://bespc.com/CDNA. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.